HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia [PDF]
Current Issues in Molecular Biology, 2023 Targeting the molecular chaperone HSP90 and the anti-apoptotic proteins MCL1 and BCL2 may be a promising novel approach in the treatment of acute myeloid leukemia (AML).
Katja Seipel +2 more
exaly +8 more sources
The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1 [PDF]
Journal of Hematology and Oncology, 2010 Background Heat shock protein 90 (HSP90) inhibitors have emerged as a promising class of anti-cancer drugs in both solid and hematologic malignancies.
Saad Z Usmani +2 more
exaly +6 more sources
Epichaperome Inhibition by PU-H71-Mediated Targeting of HSP90 Sensitizes Glioblastoma Cells to Alkylator-Induced DNA Damage [PDF]
CancersBackground: Targeted therapies have been largely ineffective against glioblastoma (GBM) owing to the tumor’s heterogeneity and intrinsic and adaptive treatment resistance.
Pratibha Sharma +2 more
exaly +5 more sources
PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond [PDF]
Frontiers in PharmacologyHeat shock protein 90 (HSP90) is a pivotal molecular chaperone with multifaceted roles in cellular health and disease. Herein, we explore how HSP90 orchestrates cellular stress responses, particularly through its partnership with heat shock factor 1 (HSF-
Sameh Saber +16 more
doaj +4 more sources
Radiosynthesis of the iodine‐124 labeled Hsp90 inhibitor PU‐H71 [PDF]
Journal of Labelled Compounds and Radiopharmaceuticals, 2016 Heat shock protein 90 (Hsp90) is an ATP dependent molecular chaperone protein whose function is critical for maintaining several key proteins involved in survival and proliferation of cancer cells. PU-H71 (1), is a potent purine-scaffold based ATP pocket
Tony Taldone +2 more
exaly +4 more sources
The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE [PDF]
Journal of Neuroimmunology, 2013 Ansamycins are very effective HSP90 inhibitors that showed significant beneficial effects in the treatment of EAE. However, their toxicity and poor stability in solution limit their clinical use.
Lucia Lisi +2 more
exaly +4 more sources
PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction
Pharmacological Research, 2015 Despite recent advances in precision medicine, many molecular-based antineoplastic agents do not potentiate sustainable long term remissions, warranting the investigation of novel therapeutic strategies.
Matthew Trendowski
exaly +4 more sources
In Vitro Purging of Acute Lymphoblastic Leukemia (B-ALL) Cells with the Use of PTL, DMAPT, or PU-H71. [PDF]
Int J Mol SciAcute lymphoblastic leukemia (ALL) is a hematopoietic disorder that mainly affects the child population, and it is characterized by the presence of lymphoid progenitor or precursor cells with different genetic alterations.
Ortiz-Reyes AE +11 more
europepmc +4 more sources
PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy [PDF]
Journal of Radiation Research, 2016 PU-H71, a Heat shock protein 90 (Hsp90) inhibitor, has yielded therapeutic efficacy in many preclinical models and is currently in clinical trials. Carbon-ion radiotherapy (CIRT) has provided successful tumor control; however, there is still a room for ...
Huizi Keiko Li +2 more
exaly +4 more sources
Synthesis and evaluation of cell-permeable biotinylated PU-H71 derivatives as tumor Hsp90 probes [PDF]
Beilstein Journal of Organic Chemistry, 2013 The attachment of biotin to a small molecule provides a powerful tool in biology. Here, we present a systematic approach to identify biotinylated analogues of the Hsp90 inhibitor PU-H71 that are capable of permeating cell membranes so as to enable the ...
Tony Taldone +2 more
exaly +4 more sources